Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro
Inflammopharmacology · 2024
DOI: 10.1007/s10787-024-01525-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Inflammopharmacology, 2024. Verfasst von Débora Bublitz Anton und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Graduate Program, Universidade do Vale do Taquari (Univates), Lajeado, CEP 95914-014, Brazil. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, SARS-CoV-2, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 199 Literaturangaben.
Abstract (Originalsprache)
In severe COVID-19 cases, an exacerbated inflammatory response triggers a cytokine storm that can worsen the prognosis. Compounds with both antiviral and anti-inflammatory activities show promise as candidates for COVID-19 therapy, as they potentially act against the SARS-CoV-2 infection regardless of the disease stage. One of the most attractive drug targets among coronaviruses is the main protease (MPro). This enzyme is crucial for cleaving polyproteins into non-structural proteins required for viral replication. The aim of this review was to identify SARS-CoV-2 MPro inhibitors with both antiviral and anti-inflammatory properties. The interactions of the compounds within the SARS-CoV-2 MPro binding site were analyzed through molecular docking when data from crystallographic structures were unavailable. 18 compounds were selected and classified into five different superclasses. Five of them exhibit high potency against MPro: GC-376, baicalein, naringenin, heparin, and carmofur, with IC50 values below 0.2 μM. The MPro inhibitors selected have the potential to alleviate lung edema and decrease cytokine release. These molecules mainly target three critical inflammatory pathways: NF-κB, JAK/STAT, and MAPK, all previously associated with COVID-19 pathogenesis. The structures of the compounds occupy the S1/S2 substrate binding subsite of the MPro. They interact with residues from the catalytic dyad (His41 and Cys145) and/or with the oxyanion hole (Gly143, Ser144, and Cys145), which are pivotal for substrate recognition. The MPro SARS-CoV-2 inhibitors with potential anti-inflammatory activities present here could be optimized for maximum efficacy and safety and be explored as potential treatment of both mild and severe COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biotechnology Graduate Program, Universidade do Vale do Taquari (Univates), Lajeado, CEP 95914-014, Brazil.
- Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, 72076, Tübingen, Germany.
- Biotechnology Graduate Program, Universidade do Vale do Taquari (Univates), Lajeado, CEP 95914-014, Brazil. luis.timmers@univates.br.
- Medical Science Graduate Program, Universidade do Vale do Taquari (Univates), Lajeado, CEP 95914-014, Brazil. luis.timmers@univates.br.
Zitieren
APA
Anton, D. B., de Lima, J. C., Dahmer, B. R., Camini, A. M., Goettert, M. I., & Timmers, L. F. S. M. (2024). Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro. Inflammopharmacology. https://doi.org/10.1007/s10787-024-01525-9
Vancouver
Anton DB, de Lima JC, Dahmer BR, Camini AM, Goettert MI, Timmers LFSM. Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro. Inflammopharmacology. 2024. doi:10.1007/s10787-024-01525-9
BibTeX
@article{Anton2024,
author = {Anton, Débora Bublitz and de Lima, Jeferson Camargo and Dahmer, Bruno Rampanelli and Camini, Ana Micaela and Goettert, Marcia Inês and Timmers, Luis Fernando Saraiva Macedo},
title = {Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro},
journal = {Inflammopharmacology},
year = {2024},
doi = {10.1007/s10787-024-01525-9}
}
EUVIMED